1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...
1. Compared to placebo, children who received peanut oral immunotherapy experienced significantly greater desensitization and remission. 2. Younger age at ...
Click to read this study in Lancet Oncology.
Click to read this study in JAMA Network Open.
1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% ...
Click to read the study in Clinical Cancer Research.
1. Camrelizumab and apatinib treatment provided a 55% objective response rate 2. A complete response was observed in 50% of ...
Click to read the study in The Lancet.
Click to read the study in the Journal of Investigative Dermatology.
Click to read the study in the European Journal of Cancer.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.